Lava Therapeutics
Utrecht
About Lava Therapeutics
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation ╬│╬┤ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $102.9M
- Funding stage: M&A
- Last round: Series C (Sep 2020)
- Ticker: nasdaq:LVTX
- Website: lavatherapeutics.com
- Phone: +31 8 506 573 44
Industries & Categories
Biotechnology, Life Science, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/lava-therapeutics-81991 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.